Skip to main content

Table 3 Univariate and multivariate analysis of overall survival (OS) for breast cancer patients who received adjuvant CIK cell immunotherapy

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Variables Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age (< 50 vs. ≥ 50) 1.031 0.670–1.231 0.747    
Tumor size (<  20 vs. ≥ 20) (mm) 2.918 1.554–4.609 < 0.001* 1.895 0.881–2.805 0.493
TNM stage (I-II vs. III) 1.732 1.275–2.618 0.013* 1.787 1.271–2.991 0.015*
Histological differentiation (I-II vs. III) 1.078 0.487–1.499 0.718    
Positive lymph node ratio (< 0.21 vs. ≥ 0.21) 2.004 0.812–2.260 0.083    
ER (pos vs. neg) 0.714 0.513–1.919 0.057    
PR (pos vs. neg) 0.721 0.486–1.542 0.501    
Herb2 (pos vs. neg) 1.405 1.207–2.711 0.029* 1.193 0.814–2.569 0.807
PD-L1 expression (pos vs. neg) 0.610 0.352–0.903 < 0.001* 0.569 0.318–0.830 < 0.001*
TNBC (yes vs. no) 1.902 0.890–2.925 0.604    
  1. HR Hazard ratio, CI Confidence interval, *Statistically significant, p <  0.05